These findings highlight the potential synergistic role of EGFR amplification and EGFR mutations in tumor development, increasing the molecular dependence of these tumors on the EGFR pathway and potentially improving sensitivity to EGFR‐TKI treatment [14, 15]. The gene discussed is EGFR; the disease is neoplasm.